FrancophonIA/ELRC3.0 huggingface dataset:
English: Reagila 1.5 mg hard capsules ‘Size 4' (approximately 14.3 mm in length) hard gelatin capsule with white opaque cap and white opaque body imprinted with “GR 1.5” on the capsule body with black ink.
Estonian: Kuidas Reagila välja näeb ja pakendi sisu - Reagila 1,5 mg kõvakapslid: Valge läbipaistmatu kapslikaane ja valge läbipaistmatu kapslikehaga kõva želatiinkapsel suurusega ‘4' (ligikaudu 14,3 mm pikk), mille kehale on musta tindiga trükitud “GR 1.5”.
English: Parkinsonism was experienced in 13.6%; 5.7%; 22.1% and 5.3% in patients treated with cariprazine, placebo, risperidone and aripiprazole respectively.
Estonian: Kariprasiini, platseebot, risperidooni ja aripiprasooli saavatest patsientidest koges parkinsonismi vastavalt 13,6%, 5,7%, 22,1% ja 5,3% patsientidest.
English: Gastrooesopha geal reflux disease
Estonian: Gastroösofageaalne reflukshaigus
English: Cariprazine should be used cautiously in patients with history of seizures or with conditions that potentially lower the seizure threshold.
Estonian: Patsientidel, kellel on anamneesis esinenud krambihoogusid või seisundeid, mis võivad alandada krambiläve, tuleb kariprasiini kasutada ettevaatusega.
English: Brilliant blue FCF (E 133) Allura red AC (E 129) Titanium dioxide (E 171) Gelatin
Estonian: Kapslikest (6 mg) Briljantsinine FCF (E133) Alluurpunane AC (E129) Titaandioksiid (E171)
English: Thirst
Estonian: Düsfaagia
English: Dysphagia
Estonian: QTpikenemine
English: - dizziness on standing up due to a drop in your blood pressure, which may cause fainting - a history of blood clots, or if someone else in your family has a history of blood clots, as medicines for schizophrenia have been associated with formation of blood clots - a history of stroke, especially if you are elderly or know that you have other risk factors for stroke.
Estonian: - teil või kellelgi teie perekonnast on olnud verehüübeid, kuna skisofreenia ravimite kasutamist on seostatud verehüüvete tekkimisega.
English: Black iron oxide (E 172) Propylene glycol Potassium hydroxide
Estonian: must raudoksiid (E172), propüleenglükool, kaaliumhüdroksiid).
English: dyskinesia
Estonian: KÕLBLIKKUSAEG
English: Tachyarrhytmi a
Estonian: T- saki häire
English: ‘Size 4' (approximately 14.3 mm in length) hard gelatin capsule with green opaque cap and white opaque body imprinted with “GR 3” on the capsule body with black ink.
Estonian: Rohelise läbipaistmatu kapslikaane ja valge läbipaistmatu kapslikehaga kõva želatiinkapsel suurusega ‘4' (ligikaudu 14,3 mm pikk), mille kehale on musta tindiga trükitud “GR 3”.
English: Odefsey contains three active substances.
Estonian: Odefsey sisaldab kolme toimeainet.
English: What measures are being taken to ensure the safe and effective use of Odefsey?
Estonian: Mis meetmed võetakse, et tagada Odefsey ohutu ja efektiivne kasutamine?
English: Other information about Odefsey
Estonian: Muu teave Odefsey kohta
English: The full EPAR for Odefsey can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Odefsey kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Odefsey does not cure HIV-1 infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS.
Estonian: Odefsey ei ravi HIV-1 nakkust ega AIDSi välja, kuid võib immuunsüsteemi kahjustumist ning AIDSiga seotud nakkuste ja haiguste teket edasi lükata.
English: Odefsey must not be used with the following medicines as they may lead to reduced blood levels of rilpivirine, and thereby reduce the effectiveness of Odefsey:
Estonian: Odefseyd ei tohi kasutada koos järgmiste ravimitega, sest need võivad vähendada vere rilpiviriinisisaldust ja seega Odefsey efektiivsust:
English: By blocking this enzyme, Odefsey reduces the amount of HIV-1 in the blood and keeps it at a low level.
Estonian: Blokeerides selle ensüümi, vähendab Odefsey HIV-1 kogust veres ja hoiab selle sisalduse väikese.
English: The CHMP therefore decided that Odefsey's benefits are greater than its risks and recommended that it be approved for use in the EU.
Estonian: Inimravimite komitee otsustas, et Odefsey kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
English: This means that the effects of these components in Odefsey should be similar to their effects in other medicines.
Estonian: See tähendab, et Odefsey nende koostisosade toimed on teiste ravimite samade koostisosade toimetega sarnased.
English: • rifabutin, rifampicin, rifapentine (antibiotics);
Estonian: • rifabutiin, rifampitsiin, rifapentiin (antibiootikumid);
English: Why is Odefsey approved?
Estonian: Miks Odefsey heaks kiideti?
English: What is Odefsey and what is it used for?
Estonian: Mis on Odefsey ja milleks seda kasutatakse?
English: In terms of safety, tenofovir alafenamide is effective at a lower dose than tenofovir disoproxil and may lead to reduced side effects in the kidneys and bones.
Estonian: Ohutuse seisukohalt on tenofoviiralafenamiid efektiivne väiksemas annuses kui tenofoviirdisoproksiil ja võib põhjustada neerudes ja luudes vähem kõrvalnähte.
English: Odefsey is available as tablets, each containing 200 mg emtricitabine, 25 mg rilpivirine, and 25 mg tenofovir alafenamide.
Estonian: Odefseyd turustatakse tablettidena, mis sisaldavad 200 mg emtritsitabiini, 25 mg rilpiviriini ja 25 mg tenofoviiralafenamiidi.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) considered that Odefsey is an alternative treatment option to Eviplera with similar effectiveness.
Estonian: Inimravimite komitee leidis, et Odefsey on Eviplerale alternatiivne ravim, millel on samasugune efektiivsus.
English: • dexamethasone (a corticosteroid medicine used to treat inflammation and suppress the immune system) except when used as a single dose treatment;
Estonian: • deksametasoon (kortikosteroidravim, mida kasutatakse põletiku raviks ja immuunsüsteemi pärssimiseks), välja arvatud üksikannustega ravis kasutamisel;
English: This is a summary of the European public assessment report (EPAR) for Odefsey.
Estonian: See on ravimi Odefsey Euroopa avaliku hindamisaruande kokkuvõte.
English: It is not intended to provide practical advice on how to use Odefsey.
Estonian: Hindamisaruandes ei anta Odefsey kasutamise praktilisi nõuandeid.
English: In addition, to support its application, the company performed a ‘bioequivalence' study comparing Odefsey with two other HIV medicines: Edurant (rilpivirine) and Genvoya (elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide).
Estonian: Lisaks viis ettevõte oma taotluse toetamiseks läbi bioekvivalentsuse uuringu, milles võrdles Odefseyd kahe teise HIV-i ravimiga, Eduranti (rilpiviriin) ja Genvoyaga (elvitegraviir, kobitsistaat, emtritsitabiin ja tenofoviiralafenamiid).
English: What are the risks associated with Odefsey?
Estonian: Mis riskid Odefseyga kaasnevad?
English: To support the use of tenofovir alafenamide, the company provided data from studies showing that combination medicines containing tenofovir alafenamide are as effective in reducing the amount of HIV-1 in the blood as those containing tenofovir disoproxil.
Estonian: Ettevõte esitas tenofoviiralafenamiidi kasutamise toetuseks uuringute andmed, mis näitavad, et tenofoviiralafenamiidi sisaldavad kombineeritud ravimid on HIV-1 koguse vähendamisel veres sama efektiivsed kui tenofoviirdisoproksiili sisaldavad ravimid.
English: • omeprazole, esomeprazole, dexlansoprazole, lansoprazole, pantoprazole, rabeprazole (medicines for reducing stomach acid);
Estonian: • omeprasool, esomeprasool, dekslansoprasool, lansoprasool, pantoprasool, rabeprasool (maohapet vähendavad ravimid);
English: For practical information about using Odefsey, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Odefsey kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: Odefsey emtricitabine / rilpivirine / tenofovir alafenamide
Estonian: Odefsey emtritsitabiin / rilpiviriin / tenofoviiralafenamiid
English: How does Odefsey work?
Estonian: Kuidas Odefsey toimib?
English: It is only used in patients where the virus has not developed resistance to a class of HIV medicines called nonnucleoside reverse transcriptase inhibitors, tenofovir or emtricitabine, and who have HIV levels in the blood (viral load) of no more than 100,000 HIV-1 RNA copies/ml.
Estonian: Odefseyd kasutatakse ainult patsientidel, kellel esinev viirus ei ole veel resistentne HIV- ravimite mittenukleosiidsete pöördtranskriptaasiinhibiitorite tenofoviiri või emtritsitabiini suhtes ja kelle vere HIV-sisaldus (viiruskoormus) ei ole suurem kui 100 000 HIV-1 RNA koopiat/ml.
English: The most common side effects seen with the active substance rilpivirine and with the combination of emtricitabine and tenofovir alafenamide (which may affect more than 1 in 10 people) are headache, dizziness and nausea (feeling sick).
Estonian: Toimeaine rilpiviriini ning emtritsitabiini ja tenofoviiralafenamiidi kombinatsiooni kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peavalu, peapööritus ja iiveldus.
English: For more information about treatment with Odefsey, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Odefseyga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Very common side effects with rilpivirine also include increased cholesterol levels (total cholesterol and LDL-cholesterol), insomnia (difficulty sleeping) and increased liver and pancreas enzymes.
Estonian: Rilpiviriini väga sageli esinevad kõrvalnähud on ka kolesteroolisisalduse (üldkolesterooli ja LDL-kolesterooli) suurenemine, unetus (magamisraskused) ning maksa- ja kõhunäärmeensüümide sisalduse suurenemine.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Odefsey have been included in the summary of product characteristics and the package leaflet.
Estonian: Odefsey omaduste kokkuvõttesse ja pakendi infolehele lisati ravimi ohutu ja tõhusa kasutamise teave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: This study showed that Odefsey produces the same levels of rilpivirine in the body as Edurant, and the same levels of emtricitabine and tenofovir alafenamide as Genvoya.
Estonian: Uuring näitas, et Odefsey annab organismis sama rilpiviriini sisalduse kui Edurant ja sama emtritsitabiini ja tenofoviiralafenamiidi sisalduse kui Genvoya.
English: All three active substances block the activity of reverse transcriptase, a virus enzyme that allows HIV-1 to replicate in the cells it has infected.
Estonian: Pöördtranskriptaas on viiruse ensüüm, mis võimaldab HIV-1-l nakatatud rakkudes paljuneda.
English: What benefits of Odefsey have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Odefsey kasulikkus?
English: Odefsey contains the active substances emtricitabine, rilpivirine and tenofovir alafenamide.
Estonian: Odefsey sisaldab toimeainetena emtritsitabiini, rilpiviriini ja tenofoviiralafenamiidi.
English: Tenofovir and emtricitabine are related antiviral agents called reverse transcriptase inhibitors.
Estonian: Tenofoviir ja emtritsitabiin on viirusevastaste ainete pöördtranskriptaasiinhibiitorite lähedalt seotud tüübid.
English: Odefsey is an antiviral medicine used to treat adults and adolescents (aged over 12 years and weighing at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1), a virus that causes acquired immune deficiency syndrome (AIDS).
Estonian: Odefsey on viiruseravim, mida kasutatakse omandatud immuunpuudulikkuse sündroomi (AIDS) põhjustava inimese immuunpuudulikkuse 1. tüüpi viiruse (HIV-1) infektsiooni raviks täiskasvanutel ja noorukitel (vanuses üle 12 aasta ja kehamassiga vähemalt 35 kg).
English: How is Odefsey used?
Estonian: Kuidas Odefseyd kasutatakse?
English: • St John's wort (a herbal preparation used for depression and anxiety).
Estonian: • naistepuna (taimne depressiooni ja ärevuse ravim).
English: The combination of active substances in Odefsey (emtricitabine, rilpivirine and tenofovir) is already approved in the EU as Eviplera to treat HIV-1 infection, although in Eviplera tenofovir is present as tenofovir disoproxil whereas in Odefsey it is present as tenofovir alafenamide.
Estonian: Odefsey toimeainete kombinatsioon (emtritsitabiin, rilpiviriin ja tenofoviir) on juba saanud Euroopa Liidus müügiloa HIV-1 nakkuse raviks Eviplera nime all.
English: Rilpivirine is an antiviral agent called non-nucleoside reverse transcriptase inhibitor.
Estonian: Rilpiviriin on viirusevastane aine, mittenukleosiidne pöördtranskriptaasiinhibiitor.
English: For the full list of all side effects, see the package leaflet.
Estonian: Odefsey kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Content Package size
Estonian: Pakendi sisu Pakendi suurus
English: Safety was comparable between the groups.
Estonian: Ohutus oli neis rühmades võrreldav.
English: In total 692 patients were enrolled.
Estonian: Uuringutes osales kokku 692 patsienti.
English: The bibliographic data submitted provide evidence to support the indications:
Estonian: Esitatud bibliograafilised andmed toetavad näidustusi:
English: An indication that includes relief of symptoms in this population, however, is not sufficiently supported.
Estonian: Näidustust, mis sisaldaks sümptomite leevendamist sellel populatsioonil, ei ole aga piisavalt toetatud.
English: All three have a very limited potential for drug interactions at the CYP level (Unge and Andersson 1997).
Estonian: Kõigil kolmel on ravimite koostoime potentsiaal CYP tasandil väga piiratud (Unge and Andersson 1997).
English: Relief of symptoms is obtained rapidly.
Estonian: Sümptomite leevenemine saavutatakse kiiresti.
English: The limited data as regards lansoprazole support this.
Estonian: Piiratud andmed lansoprasooli kohta toetavad seda.
English: petechia, purpura,
Estonian: Petehhiad, purpura,
English: Rare (0.01-0.1%) Very Rare
Estonian: Harv (0,01...0,1%) Väga harv
English: Senses taste disturbances and visual disturbances.
Estonian: Maitsetundlikkuse häired ning nägemishäired.
English: The primary endpoint was recurrence of symptomatic and complicated ulcers during the 8 weeks.
Estonian: Esmane lõpp punkt oli sümptomaatiliste komplitseeritud haavandite kordumine 8 nädala vältel.
English: Instructions for Use and Handling
Estonian: Kasutamis- ja käsitsemisjuhend
English: Lansoprazol HEXAL 15 mg, 30 mg, gastro-resistant capsules, hard were referred for arbitration according to Article 29 of Council Directive 2001/83/EC, as amended, following concerns raised by Germany during a Mutual Recognition Procedure with Finland acting as Reference Member state.
Estonian: Lansoprazol HEXAL 15 mg, 30 mg gastroresistentsete kõvakapslite küsimus suunati lahendamiseks vastavalt nõukogu muudetud direktiivi 2001/83/EÜ artiklile 29 pärast Saksamaa poolt vastastikuse tunnustamise menetluses Soomega kui võrdlusliikmesriigiga tõstatatud probleeme.
English: Overall rate of healing according to Sakitas classification was 95%.
Estonian: Üldine paranemisprotsent Sakitase klassifikatsiooni järgi oli 95%.
English: At 4 weeks, the corresponding healing rates were 30%, 47% and 57%.
Estonian: 4. nädalal olid vastavad paranemismäärad 30%, 47% ja 57%.
English: Benefit/Risk considerations
Estonian: Kasulikkusest ja riskist tulenevad kaalutlused
English: bronchial constriction, impotence and angioedema.
Estonian: bronhide konstriktsioon, impotentsus ja angioödeem.
English: Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.
Estonian: Loomkatsetes ei ole leitud otseseid või kaudseid kahjulikke toimeid tiinusele, embrüo ja loote arengule, poegimisele või postnataalsele arengule.
English: If the required daily dose exceeds 120 mg, it should be given in two divided doses.
Estonian: Kui ööpäevane vajalik annus ületab 120 mg, tuleb annus jagada kaheks manustamiskorraks.
English: A single oral dose of 30 mg reduces basal secretion by about 70%, and the patients' symptoms are consequently relieved starting from the very first dose.
Estonian: Ühekordne suukaudne 30 mg annus vähendab basaalsekretsiooni ligikaudu 70% ja patsiendi sümptomid leevenevad juba esimesest doosist alates.
English: Absorption from the duodenum is rapid and plasma peak concentration is achieved within 1.5-2.0 hours.
Estonian: Imendumine kaksteistsõrmiksoolest on kiire ja maksimaalne plasma kontsentratsioon saavutatakse 1,5...2,0 tunni jooksul.
English: Endoscopy was also performed at week 8.
Estonian: 8. nädalal sooritati ka endoskoopia.
English: the CHMP has recommended the granting of the Marketing Authorisations with amendments of the Summary of Product Characteristics as set out in Annex III for Lansoprazol HEXAL and associated names (see Annex I).
Estonian: on inimtervishoius kasutatavate ravimite komitee soovitanud anda müügiload ravimi omaduste kokkuvõtte muudatustega, mis on esitatud lisas III Lansoprazol HEXAL-i ja sellega seotud nimede kohta (vt lisa I).
English: Compared with placebo, lansoprazole only reduced the need for antacids in one of the studies but significant difference with regard to symptoms was not shown.
Estonian: Lansoprasool võrreldes platseeboga ainult vähendas antatsiidide vajadust ühes uuringus, kuid olulist vahet sümptomite suhtes ei tõendatud.
English: pancreatitis colitis, stomatitis and black tongue
Estonian: Koliit, stomatiit ja must keel.
English: Healing was assessed endoscopically at 4 and 8 weeks.
Estonian: Paranemist hinnati endoskoopiliselt 4. ja 8. nädalal.
English: Ulcer status was determined by endoscopy at week 4, 8, and 12.
Estonian: Haavandi seisund määrati kindlaks endoskoopiliselt 4., 8. ja 12. nädalal.
English: Concomitantly taken food slows down and reduces the absorption of lansoprazole.
Estonian: Samaaegne toidu tarbimine aeglustab ning vähendab lansoprasooli imendumist.
English: For duodenal ulcers (n=46), the healing rates were between 81%-93% at week 8 in the 3 treatment groups.
Estonian: Kaksteistsõrmikuhaavandite puhul (n=46) olid paranemismäärad 8. nädalal 3 ravirühmas vahemikus 81%-93%.
English: Metabolism and elimination: The metabolism of lansoprazole is mainly catalysed by the enzyme CYP2C19.
Estonian: Metabolism ja eliminatsioon: Lansoprasooli metabolismi katalüüsib peamiselt ensüüm CYP2C19.
English: It may not be excluded that lanzoprazole may affect transport via this protein giving rise to increased plasma concentrations of P-gp substrates such as digoxin.
Estonian: Ei saa välistada, et lansoprasool mõjutab transporti selle proteiini kaudu, põhjustades P-glükoproteiini substraatide, nagu näiteks digoksiini, plasmakontsentratsioonide suurenemist.
English: The scope of the referral was to agree on a Summary of Products Characteristics in view of the indication.
Estonian: Arvestades, et: suunamise ulatuseks oli leppida kokku ravimi omaduste kokkuvõtte suhtes, pidades silmas näidustust,
English: In patients receiving NSAIDs with H. pylori infection gastric ulcer healing with an antisecretory agent was significantly enhanced (70% vs 61%, P<0.05).
Estonian: Patsientidel, kes kasutasid mittesteroidseid põletikuvastaseid ravimeid, oli H. pylori infektsiooniga maohaavandi ravi antisekretoorse ainega oluliselt tõhusam (70% võrreldes 61%-ga, P<0,05).
English: Patients with duodenal ulcers (n=3) were treated for 6 weeks and patients with gastric ulcers (n=42) or multiple ulcers (n=5) for 8 weeks.
Estonian: Kaksteistsõrmikuhaavandiga patsiente (n=3) raviti 6 nädalat ja maohaavandiga (n=42) või mitme haavandiga patsiente (n=5) 8 nädalat.
English: 15 mg once daily.
Estonian: 15 mg üks kord ööpäevas.
English: The rate of S2-healing (good healing) was
Estonian: S2-paranemise (hea paranemise) määr oli 35%.
English: If lansoprazole, in combination with antibiotics, is used for eradication therapy of H.-pylori, then also instructions for the use of these antibiotics should be followed.
Estonian: Kui lansoprasooli kasutatakse H. pylori eradikatsiooniks koos antibakteriaalsete ainetega, tuleb järgida ka manustatavate antibiootikumide kasutusjuhiseid.
English: It inhibits the final stage of gastric acid formation by inhibiting the activity of H +/K
Estonian: Ta inhibeerib maohappe moodustumise lõppetappi, inhibeerides H
English: There is scarce data concerning healing rates for duodenal ulcers but duodenal ulcers are known in general to heal better than gastric ulcers following acid suppression.
Estonian: Kaksteistsõrmikuhaavandite paranemise määrade kohta on andmeid vähe, kuid kaksteistsõrmikuhaavandid paranevad üldiselt paremini kui maohaavandid pärast happe supressiooni.
English: fever, hyperhidrosis,
Estonian: hüperhidroos,
English: Therefore, the benefit-risk profile of Lansoprazol HEXAL 15 mg, 30 mg in the proposed indications can be considered favourable.
Estonian: Seega võib Lansoprazol HEXAL 15 mg, 30 mg kasulikkuse ja riski profiili heakskiidetud näidustuste puhul soodsaks pidada.
English: OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF LANSOPRAZOL HEXAL 15 MG, 30 MG GASTRO-RESISTANT CAPSULES, HARD (see Annex I)
Estonian: ÜLDINE KOKKUVÕTE LANSOPRAZOL HEXAL 15 MG, 30 MG GASTRORESISTENTSETE KÕVAKAPSLITE TEADUSLIKUST HINDAMISEST (vt lisa I)
English: The proton pump inhibitors, omeprazole, lansoprazole and pantoprazole are all mainly metabolized by the cytochrome P450 isoform CYP2C19.
Estonian: Prootonpumba inhibiitoreid omeprasooli, lansoprasooli ja pantoprasooli metaboliseerib kõiki põhiliselt tsütokroom P450 isovorm CYP2C19.
English: Several clinical trials as well as extensive clinical experience has not indicated that there exist interactions when lansoprazole is given together with NSAIDs.
Estonian: Mitu kliinilist uuringut ja ulatuslikud kliinilised kogemused ei ole näidanud koostoimete esinemist lansoprasooli kasutamisel koos mittesteroidsete põletikuvastaste ravimitega.
English: The following interactions between lansoprazole and certain antibiotics used in eradication therapy have been found so far:
Estonian: Seni on kirjeldatud järgnevaid lansoprasooli ja eradikatsioonravis kasutatavate antibiootikumide vahelisi koostoimeid:
English: The cumulative incidence of symptomatic and complicated GD ulcers at week 8 was 4.5% in the lansoprazole group and 42.9% in the no treatment group (P=0.0025).
Estonian: Sümptomaatilisi ja komplitseeritud mao- ja kaksteistsõrmikuhaavandeid esines kumulatiivselt 4,5% lansoprasooli rühmas ja 42,9% ravita rühmas (P=0,0025).
English: After successful healing of the ulcers and eradication of H. pylori, patients were randomized to treatment with lansoprazole 30 mg or placebo in addition to aspirin 100 mg daily for 12 months.
Estonian: Pärast haavandite edukat paranemist ja H. pylori eradikatsiooni randomiseeriti patsiendid raviks lansoprasooliga 30 mg või platseeboga lisaks aspiriinile 100 mg päevas 12 kuu vältel.
English: Patients received eradication treatment followed by lansoprazole 30 mg for 4 weeks.
Estonian: Patsiendid said eradikatsioonravi, millele järgnes ravi lansoprasooliga 30 mg 4 nädala vältel.
English: Primary endpoint was the recurrence of ulcer complications.
Estonian: Esmane lõpp-punkt oli haavandiliste tüsistuste kordumine.
English: Whereas,
Estonian: Perifeersed tursed,
English: Patients were randomized to treatment with either ranitidine 150 mg twice daily or lansoprazole, 15 mg or 30 mg once daily for 8 weeks.
Estonian: Patsiendid randomiseeriti raviks kas ranitidiiniga 150 mg kaks korda päevas või lansoprasooliga 15 mg või 30 mg üks kord päevas 8 nädala vältel.
English: For patients at risk or with ulcers that are difficult to heal, a longer course of treatment and/or a higher dose should be considered.
Estonian: Riskipatsientidel või halvastiparanevate haavanditega patsientidel võib kaaluda ravi rakendamist pikema aja jooksul või suuremas annuses.